VXRT
Vaxart, Inc.
VXRT
Vaxart, Inc.
Vaxart OTCMKTS: VXRT Chief Executive Officer Steve Lo outlined the company's oral vaccine platform, its government-funded COVID-19 study and development opportunities in norovirus and influenza during
Vaxart OTCMKTS: VXRT said it has reported positive 12-month safety data from the 400-participant Sentinel cohort of its Phase II-B COVID-19 vaccine trial and remains on track to disclose top-line data
Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript
Vaxart OTCMKTS: VXRT held its 2026 Annual Meeting of Stockholders, where investors re-elected the company's full slate of directors, ratified its auditor and rejected the company's non-binding advisor
SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pi
SOUTH SAN FRANCISCO, Calif. , July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant p